GANX
MaterialsGain Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving GANX Today?
No stock-specific AI insight has been generated for GANX yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
GANX News
20 articles- 3 US Biotechs Developing Parkinson’s TherapiesYahoo Finance·May 5, 2026
- Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026Yahoo Finance·Apr 24, 2026
- Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate UpdateYahoo Finance·Mar 26, 2026
- Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth ConferenceMarketbeat·Mar 24, 2026
- Gain Therapeutics to Present at the 38th Annual ROTH ConferenceYahoo Finance·Mar 19, 2026
- Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026Yahoo Finance·Mar 18, 2026
- Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory UpdateYahoo Finance·Mar 12, 2026
- Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceYahoo Finance·Feb 19, 2026
- Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference WeekYahoo Finance·Jan 7, 2026
- Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287Yahoo Finance·Jan 6, 2026
- Gain Therapeutics (GANX) Upgraded to Buy: Here's WhyYahoo Finance·Dec 22, 2025
- Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s DiseaseYahoo Finance·Dec 18, 2025
- Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s DiseaseYahoo Finance·Dec 18, 2025
- Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to BuyYahoo Finance·Dec 8, 2025
- Gain Therapeutics’ (GANX) Preclinical Momentum Drives Its Progress in Parkinson’s Drug DevelopmentYahoo Finance·Nov 29, 2025
- Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025Yahoo Finance·Nov 20, 2025
- Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Nov 17, 2025
- Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate UpdateYahoo Finance·Nov 12, 2025
- Gain Therapeutics to Present at Neuroscience 2025Yahoo Finance·Oct 30, 2025
- Gain Therapeutics to Attend the 2025 Maxim Growth SummitYahoo Finance·Oct 16, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About Gain Therapeutics Inc
Gain Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of allosteric therapies. Its flagship drug candidate, GT-02287, is being evaluated in a Phase 1b clinical trial for the treatment of Parkinson's disease, with potential applications in Gaucher's disease, dementia with Lewy bodies, and Alzheimer's disease. The company also has multiple preclinical programs targeting lysosomal storage disorders, metabolic diseases, and solid tumors. Using its Magellan platform, the company develops allosteric small molecule modulators aimed at restoring or altering protein function to explore treatments for neurodegenerative diseases, rare genetic disorders, and oncology.